Daniel Machado

Daniel Machado is an associate in the Washington, D.C. office of Latham & Watkins and a member of the Healthcare & Life Sciences Practice.

Daniel advises pharmaceutical, biotechnology, and medical device companies as well as hospitals and other healthcare providers on complex healthcare regulatory, compliance, and reimbursement matters. He combines deep regulatory knowledge with practical, client-focused counsel to help companies navigate the evolving healthcare landscape, with particular focus on:

• Coverage, reimbursement, and market access matters involving the Centers for Medicare & Medicaid Services (CMS), including payment and coding
• Government price reporting obligations under the Medicaid Drug Rebate Program (MDRP), Medicare Part B, and the 340B drug pricing program, including advice related to the Inflation Reduction Act and Most Favored Nation issues
• Federal Anti-Kickback Statute compliance and related fraud and abuse counseling

In addition, Daniel advises private equity firms, investment banks, commercial lenders, and healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, and financing in the United States. He draws on specialized expertise in federal pricing and reimbursement frameworks to help clients evaluate regulatory risk, structure compliant arrangements, and navigate regulatory obligations in connection with corporate transactions. 

Daniel also assists clients in challenging adverse government actions through Administrative Procedure Act litigation and represents pharmaceutical and healthcare companies in government investigations, internal investigations, and regulatory audits.